Document Detail

Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men.
MedLine Citation:
PMID:  16801935     Owner:  NLM     Status:  MEDLINE    
STUDY DESIGN: Open, before-after study.
OBJECTIVE: To assess the efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction (ED) in spinal cord-injured (SCI) patients.
SETTING: Home- and clinic-based assessments in the outpatient department at the Centre Bouffard Vercelli, Cerbère France.
METHODS: Clinic trials with Sildenafil (Viagra) on 120 patients, Tadalafil (Cialis) on 54 patients and Vardenafil (Levitra) on 66 patients were performed. Flexible doses of PDE5 inhibitors were given depending on efficacy and tolerability, from 50 to 100 mg for Sildenafil, and from 10 to 20 mg for Vardenafil and Tadalafil. Each trial was performed after a week's interval. The efficacy was self-assessed by the patients on a six-point quantitative scale assessment. The response to treatment was assessed at home in 90 patients (57 patients on Sildenafil, 12 patients on Vardenafil and 21 patients on Tadalafil) using the International Index of Erectile Function (IIEF).
RESULTS: In clinic trials, PDE5 inhibitors were effective (rigidity enough for penetration) in 85% of the patients on Sildenafil, 74% of the patients on Vardenafil and 72% of the patients on Tadalafil. The mean duration of erection was 34, 28 and 26 min, respectively. Adverse effects were mild, usually attenuated with continued dosing. More than 70% of the patients on Vardenafil and Tadalafil required higher doses of 20 mg, whereas 50 mg of Sildenafil was effective in 55% of the patients. Two-thirds of our patients on Tadalafil reported a duration of action longer than 24 h. The presence of an upper motor neuron lesion was significantly associated with therapeutic success, lower motor neuron lesions and cauda equina patients were poor responders. Other variables such as completeness of lesion had no impact. In the follow-up visits, the IIEF global scores and three IIEF domains (erectile function, intercourse satisfaction and overall satisfaction) were significantly improved in all patients. Patients on Sildenafil showed a significant improvement of orgasmic function, ejaculation (Question 9) and orgasm (Question 10).
CONCLUSION: Sildenafil, Vardenafil and Tadalafil are all effective and well-tolerated treatments for ED in SCI patients. Although no statistical analysis could be applied on these data, these results might indicate that Sildenafil is more effective in treating ED. Clinic trials are important for proper dose titration and appropriate education of the patients.
J M Soler; J G Previnaire; P Denys; E Chartier-Kastler
Related Documents :
15820355 - The diagnostic value of eegs in patients with syncope.
7893295 - Unrecognized delirium in ed geriatric patients.
19655205 - Careless use of turban pins: a possible problem for turbaned patients.
2404435 - A randomized trial to improve compliance in urinary tract infection patients in the eme...
23059055 - Icu without walls project. effect of the early detection of patients at risk.
21757095 - Goal-directed therapy in small animal critical illness.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article     Date:  2006-06-27
Journal Detail:
Title:  Spinal cord     Volume:  45     ISSN:  1362-4393     ISO Abbreviation:  Spinal Cord     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-02     Completed Date:  2007-03-27     Revised Date:  2011-06-06    
Medline Journal Info:
Nlm Unique ID:  9609749     Medline TA:  Spinal Cord     Country:  England    
Other Details:
Languages:  eng     Pagination:  169-73     Citation Subset:  IM    
Centre Bouffard Vercelli, Laboratoire d'urodynamique et de sexologie, Cerbère, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Carbolines / therapeutic use
Erectile Dysfunction / drug therapy*,  etiology*
Imidazoles / therapeutic use
Middle Aged
Phosphodiesterase Inhibitors / therapeutic use*
Piperazines / therapeutic use
Purines / therapeutic use
Reaction Time / drug effects
Retrospective Studies
Spinal Cord Injuries / complications*
Sulfones / therapeutic use
Triazines / therapeutic use
Reg. No./Substance:
0/Carbolines; 0/Imidazoles; 0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 0/Triazines; 0/tadalafil; 139755-83-2/sildenafil; 224785-90-4/vardenafil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of harness application and postural changes on cardiovascular parameters of individuals with ...
Next Document:  The individual relationship between heart rate and oxygen uptake in people with a tetraplegia during...